DarioHealth Corp.: directors' dealings · United States · SEC (Form 4)

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a U.S.-listed digital health company traded on the NASDAQ market in the United States. Founded in 2011, the business originally grew out of a direct-to-consumer model and has since evolved toward a broader B2B2C strategy serving employers, health plans, pharmaceutical partners, providers, and consumers. Its operating headquarters is in New York, with parts of its technology and corporate history tied to Israel through subsidiary operations. ([dariohealth.com](https://www.dariohealth.com/articles/a-different-approach-to-health-care/?utm_source=openai)) DarioHealth’s core proposition is an integrated digital platform for chronic-condition management and whole-person care. The company positions itself as consumer-led and clinically driven, combining mobile tools, connected devices, coaching, behavioral support, and data-driven engagement. Its main solution areas now span cardiometabolic care, including diabetes, hypertension, obesity, and GLP-1 support, as well as musculoskeletal care and behavioral health. The platform is designed to improve adherence, deepen member engagement, and support measurable clinical and economic outcomes for commercial partners. ([dariohealth.com](https://www.dariohealth.com/?utm_source=openai)) From a competitive standpoint, DarioHealth operates in a crowded digital health market where differentiation depends on user retention, clinical evidence, multi-condition breadth, and the ability to sell into employer and payer channels. The acquisition of Twill materially expanded the product set by adding behavioral health and navigation capabilities, and management highlighted the full integration of those capabilities in 2024 as a step toward a more comprehensive end-to-end platform. The company’s competitive message is increasingly centered on being a multi-condition platform rather than a single-condition point solution. ([dariohealth.com](https://www.dariohealth.com/pressreleases/dario-announces-integration-twill-capabilities-across-full-platform/?lang=es&utm_source=openai)) Recent milestones point to a commercial acceleration strategy. In January 2025, DarioHealth announced a collaboration with MediOrbis to add prescribing capabilities to its GLP-1 behavior-change solution, broadening its medical weight-loss offering and supporting both employer and direct-to-consumer use cases. During 2024, the company also announced a commercial reorganization aimed at streamlining leadership and speeding revenue growth, while reporting stronger momentum in its core B2B2C channel. For investors, DarioHealth remains a small-cap growth name in healthcare technology: the opportunity is tied to platform expansion and commercial execution, while the risk profile still reflects intense competition and ongoing funding needs. ([dariohealth.com](https://www.dariohealth.com/pressreleases/dariohealth-expands-glp-1-solution-prescribing-capabilities-partnership-mediorbis-targeting-employers-d2c-markets/?utm_source=openai))